Study on the relationship between fecal marker (calprotectin, lactoferrin) and magnifying endoscopic stratification in patients with ulcerative colitis in clinical remissio
Not Applicable
Recruiting
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000027464
- Lead Sponsor
- agasaki university graduate school of Biomedecal Science Department of Gastroenterology and hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1.active UC 2.liver disease, kidney disease, heart disease, and other severe complications, all of the cases that were judged unsuitable for endoscopy. 3.pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlations between relapse rate within 1 year and magnifying endoscopic stratification
- Secondary Outcome Measures
Name Time Method 1. Correlations between fecal calprotectin, lactoferrin and magnifying endoscopic stratification 2. Correlations between fecal marker concentration and relapse rate within 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do calprotectin and lactoferrin levels correlate with endoscopic activity in UC remission patients?
What molecular pathways link fecal biomarkers to mucosal healing in ulcerative colitis?
Can magnifying endoscopy improve UC relapse prediction compared to standard fecal calprotectin testing?
Which UC subtypes show distinct calprotectin/lactoferrin profiles under endoscopic stratification?
How do fecal inflammatory markers compare to serum biomarkers in UC remission monitoring?